Analysis of Clinicopathological Characteristics and Prognosis of Carcinosarcoma of the Breast
Table 1
Clinicopathological features and treatment modalities in patients with carcinosarcoma of the breast.
Characteristics
Number of patients
%
Age
≤50
21
44.7
>50
26
55.3
Menopausal status
Premenopausal
22
46.8
Postmenopausal
25
53.2
TI (D)
<180
35
74.5
≥180
12
25.5
Tumor size
<5 cm
35
74.5
≥5 cm
12
25.5
T stage at diagnosis
T1
9
19.1
T2
26
55.3
T3
10
21.3
T4
2
4.3
N stage at diagnosis
N0
39
83.0
N1
8
17.0
Estrogen-receptor status
Positive
0
0.0
Negative
46
97.9
Unknown
1
2.1
Progesterone-receptor status
Positive
3
6.4
Negative
43
91.5
Unknown
1
2.1
HER2/neu (IHC and/or FISH) status
Positive
1
2.1
Negative
45
95.7
Unknown
1
2.1
EGFR status
Positive
16
34.0
Negative
4
8.5
Unknown
27
57.5
Therapeutic method
Surgery only
21
44.7
Comprehensive therapy
26
55.3
Breast surgery
Radical mastectomy
6
12.8
Modified radical mastectomy
37
78.7
Lumpectomy
4
8.5
Neoadjuvant chemotherapy
Yes
3
6.4
No
44
93.6
Adjuvant chemotherapy
Yes
22
46.8
No
25
53.2
Adjuvant radiation therapy
Yes
4
8.5
No
43
91.5
Adjuvant hormonal therapy
Yes
0
0.0
No
47
100.0
TI: time interval between first discomfort and first consultation; HER2: epidermal growth factor receptor 2; IHC: immunohistochemistry; FISH: fluorescent in situ hybridization technique; EGFR: epidermal growth factor receptor.
